Literature DB >> 30255201

Prognostic Factors in Adult Patients with Non-Cystic Fibrosis Bronchiectasis.

Betina Charvet Machado1, Patrícia Santos Jacques1, Louise Piva Penteado2, Paulo de Tarso Roth Dalcin3.   

Abstract

BACKGROUND: Non-cystic fibrosis bronchiectasis (NCFB) is a heterogeneous disease. There are few studies about prognostic factors in these patients. Our study aims to assess mortality rates and related factors in a cohort of patients and test the ability of the BSI and FACED scores in predicting mortality in this cohort.
METHODS: This was a prospective cohort analysis of 70 patients with NCFB recruited from May 2008 to August 2010. At baseline, patients underwent clinical evaluation, pulmonary function tests, 6-min walk test, and quality of life assessment. Outcomes were defined as favorable (survivors) and unfavorable (survivors who underwent lung transplantation and death from all causes). Baseline records provided data for determination of BSI and FACED.
RESULTS: Twenty-seven patients (38.57%) died and 1 (1.43%) underwent lung transplantation. Mean time for occurrence of unfavorable outcomes was 74.67 ± 4.00 months. Main cause of death was an acute infectious exacerbation of bronchiectasis (60.7). Cox regression identified age (p = 0.035; HR 1.04; CI 1.01-1.08), FEV1 % of predicted (p = 0.045; HR 0.97; CI 0.93-0.99), and MEP (p = 0.016; HR 0.96; CI 0.94-0.99) as independent predictors of unfavorable outcomes. FACED was better at predicting unfavorable outcomes in our cohort (log-rank test, FACED p = 0.001 and BSI p = 0.286). In ROC analysis, both scores were similar in predicting unfavorable outcomes (BSI 0.65; FACED 0.66).
CONCLUSIONS: Older age, lower FEV1 % of predicted, and lower MEP were independently linked to unfavorable outcomes. FACED and BSI were not accurate in predicting mortality in our cohort.

Entities:  

Keywords:  Mortality; Non-cystic fibrosis bronchiectasis; Prognostic factors; Survival

Mesh:

Year:  2018        PMID: 30255201     DOI: 10.1007/s00408-018-0165-z

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  24 in total

Review 1.  British Thoracic Society guideline for non-CF bronchiectasis.

Authors:  M C Pasteur; D Bilton; A T Hill
Journal:  Thorax       Date:  2010-07       Impact factor: 9.139

2.  Predicting mortality in bronchiectasis using bronchiectasis severity index and FACED scores: a 19-year cohort study.

Authors:  Huw C Ellis; Steven Cowman; Michele Fernandes; Robert Wilson; Michael R Loebinger
Journal:  Eur Respir J       Date:  2015-11-19       Impact factor: 16.671

3.  Aetiology in adult patients with bronchiectasis.

Authors:  A Shoemark; L Ozerovitch; R Wilson
Journal:  Respir Med       Date:  2007-01-12       Impact factor: 3.415

4.  Fleischner Society: glossary of terms for thoracic imaging.

Authors:  David M Hansell; Alexander A Bankier; Heber MacMahon; Theresa C McLoud; Nestor L Müller; Jacques Remy
Journal:  Radiology       Date:  2008-01-14       Impact factor: 11.105

5.  Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score.

Authors:  Miguel Á Martínez-García; Javier de Gracia; Monserrat Vendrell Relat; Rosa-Maria Girón; Luis Máiz Carro; David de la Rosa Carrillo; Casilda Olveira
Journal:  Eur Respir J       Date:  2013-11-14       Impact factor: 16.671

6.  Bronchiectasis: an orphan disease with a poorly-understood prognosis.

Authors:  T Keistinen; O Säynäjäkangas; T Tuuponen; S L Kivelä
Journal:  Eur Respir J       Date:  1997-12       Impact factor: 16.671

7.  Trends in bronchiectasis mortality in England and Wales.

Authors:  Helen J Roberts; Richard Hubbard
Journal:  Respir Med       Date:  2010-03-19       Impact factor: 3.415

8.  Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis.

Authors:  Miguel Angel Martínez-García; Juan-Jose Soler-Cataluña; Miguel Perpiñá-Tordera; Pilar Román-Sánchez; Joan Soriano
Journal:  Chest       Date:  2007-11       Impact factor: 9.410

Review 9.  Non-cystic fibrosis bronchiectasis.

Authors:  Pamela J McShane; Edward T Naureckas; Gregory Tino; Mary E Strek
Journal:  Am J Respir Crit Care Med       Date:  2013-09-15       Impact factor: 21.405

Review 10.  Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis.

Authors:  James D Chalmers; Adam T Hill
Journal:  Mol Immunol       Date:  2012-10-22       Impact factor: 4.407

View more
  3 in total

1.  Prevalence and characterization of chronic rhinosinusitis in patients with non-cystic fibrosis bronchiectasis at a tertiary care center in the United States.

Authors:  Shaan N Somani; Jason H Kwah; Chen Yeh; David B Conley; Leslie C Grammer; Robert C Kern; Michelle Prickett; Robert P Schleimer; Stephanie S Smith; Whitney W Stevens; Bruce K Tan; Kevin C Welch; Anju T Peters
Journal:  Int Forum Allergy Rhinol       Date:  2019-10-07       Impact factor: 3.858

2.  Clinical impact of cardiovascular disease on patients with bronchiectasis.

Authors:  Shanshan Chen; Aimin Qiu; Zhang Tao; Hailin Zhang
Journal:  BMC Pulm Med       Date:  2020-04-23       Impact factor: 3.317

3.  Which scoring system is better in association with exercise capacity and health status in noncystic fibrosis bronchiectasis patients?

Authors:  Yelda Varol; Hülya Doğan Şahin; Nimet Aksel; Ali Kadri Çırak
Journal:  Turk J Med Sci       Date:  2021-04-30       Impact factor: 0.973

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.